Logo

Alnylam Presents 18-Month Results in the P-III (HELIOS-A) Study of Vutrisiran for hATTR Amyloidosis with Polyneuropathy at ESC 2022

Share this

Alnylam Presents 18-Month Results in the P-III (HELIOS-A) Study of Vutrisiran for hATTR Amyloidosis with Polyneuropathy at ESC 2022

Shots:

  • The 18mos. analysis of exploratory cardiac endpoints in the P-III (HELIOS-A) study evaluates vutrisiran (25mg, SC, q3mos.) vs patisiran (0.3 mg/kg, IV, q3w) in a ratio (3:1) in 164 patients with ATTR amyloidosis at 57 sites in 22 countries
  • The results showed improvements in NT-proBNP & echocardiographic parameters in the cardiac subpopulation along with consistent beneficial effects on cardiac measures in the mITT group. In a planned cohort, reduction in technetium uptake in patients with high-grade uptake at baseline
  • Additionally, 96% maintained a stable grade or improved by ≥1 grade in the Perugini grading scale & 50% showed a ≥1-grade improvement @18mos. in patients with Perugini grade ≥1 at baseline

Ref: Businesswire| Image: Alnylam

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions